

FIG. 1




FIG. 2




FIG. 3A





FIG. 3B



	Placebo	0.5 mg	1 mg	2 mg
24-h Urine Aldosterone (ng/g)*	(N = 64)	(N = 54)	(N = 41)	(N = 41)
LSM (SE)	-1.7 (30.5)	-188 (33.3)	-191 (38.2)	-268 (38.2)
LSM difference (SE)		-186.4 (45.3)	-189.1 (48.8)	-265.8 (49.0)
95% CI		(-276, -97)	(-285, -93.0)	(-362, -169)
p-value		<0.0001	0.0001	<0.0001

*Aldosterone (ng/g) in the 24-hour urine sample was normalized with urinary creatinine

4/35

FIG. 3C




FIG. 3D




FIG. 4A
Serum Aldosterone Concentration




FIG. 4B
Plasma Renin Activity




FIG. 5





FIG. 6



8/35

FIG. 7





FIG. 8



Study week	-2	0	2	4	6	8	9	10	12	Δ from Baseline
N	241	242	225	209	182	148	133	122	98	
Mean SBP, mmHg										
PT completed 8 weeks	149	147	138	134	133	128				-18.7
PT completed 12 weeks	150	146	137	135	133	127	130	131	131	-15.4

FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B






FIG. 11C

Serum Total Cortisol



16/35


FIG. 12A



SUBSTITUTE SHEET (RULE 26)

17/35

FIG. 12B



SUBSTITUTE SHEET (RULE 26)

FIG. 13

	2-4 weeks	8-weeks	4-weeks	
Screening	Run-In	Part 1: QD Double-Blind Treatment	Part 2: QD Single-Blind	Safety/OLE
Stable medication regimen	Single-blind run-in to assess adherence	0.5 mg		Follow-Up (2 weeks) or enroll in OLE
		1 mg	2 mg	
		2 mg		
		Placebo		
	Remain on background anti-hypertensive medication(s)		Remove background Tx	
Patient Flow		249 Randomized → 227 Completers		
			213 Randomized → 201 Completers	
				175 Randomized**

FIG. 14






FIG. 15A



21/35

FIG. 15B



22/35

FIG. 16




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 18A





FIG. 18B



26/35

FIG. 18C






FIG. 19



SUBSTITUTE SHEET (RULE 26)


27/35

FIG. 20




28/35

FIG. 21A



29/35


FIG. 21B



SUBSTITUTE SHEET (RULE 26)


30/35

FIG. 21C




31/35

FIG. 21D



32/35

FIG. 22



SUBSTITUTE SHEET (RULE 26)

FIG. 23




FIG. 24




FIG. 25

